__________________________________________________________________________________________
22/APR/2014
Re: Local ID TH140202165/ TH201402006303 FU (1)
Thank you for reporting to us a serious adverse event related to Lilly product.
We would like to collect more information to better understanding the reported event.
Please respond to following questions regarding the adverse event – Death involving a female patient, who was subscribed Forteo, reported the event to Lilly on 19/FEB/2014.
Please send an HCP letter with the following questions:
1. What is the patient's age / date of birth?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
2. What was the patient medical history prior to the start of teriparatide?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
3. What was the basis for the diagnosis of sepsis (clinical features, multiorgan failure, presence of hypotension etc. – please enumerate)?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
4. Was there a primary focus of infection (please provide details)?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
5. What other concomitant meds or substances (including OTC, herbal, tobacco, alcohol, illicit drugs, recently discontinued drugs)?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
6. What was the duration of use of teriparatide prior to the events?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
7. Please provide the autopsy results (with toxicology).
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
8. Were the patient's death and sepsis possibly related to the use of teriparatide? (Provide the rationale for any “not related” opinion.)
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
Thanks
Yours sincerely,
ELI LILLY AND COMPANY
Sasithorn Suntharo
Pharmacovigilance Associate
HCP’s signature:
Date:
_________________________________________________________________________________
For Eli Lilly internal use only
Date of Confirmation of FU request sent to HCP:
Name and Designation: